GSK signs agreement with BARDA for anthrax treatment

GlaxoSmithKline announced on Thursday that it has signed a four-year contract with the Biomedical Advanced Research and Development Authority for the provision of its inhalation anthrax treatment, raxibacumab.

In the new contract, GSK will give the United States government 60,000 doses of raxibacumab over a four year period. The estimated value of these shipments total $196 million.

"We have been collaborating with BARDA for a number of years and raxibacumab is now an important part of the U.S. Government's emergency counter measures against bioterrorism," Sheri Mullen, the vice president of Immunology & Rare Diseases at the US Pharmaceuticals of GSK, said. "Through this agreement, we are proud to be helping protect US citizens against such threats."

Raxibacumab was approved by the FDA in December 2012. Raxibacumab is a drug that treats the Bacillus anthracis strain of anthrax in both adult and pediatric patients. The drug, however, does need to be taken in combination with appropriate antibacterial drugs.

"As a pharmaceutical company we believe we have a responsibility to support governments in protecting their citizens against infectious diseases," Mary Kerr, the global commercial leader for infectious diseases at GSK, said. "This agreement highlights the ongoing successful collaboration between GSK and BARDA and is just one example of our commitment to working with governments globally to fight major public health threats."